Dibenzothiazoles as novel amyloid-imaging agents
Chunying Wu1, Jingjun Wei, Kuanqiang Gao
1Department of Chemistry and Radiology, Case Western Reserve University, Cleveland, OH 44106, USA.
Bioorganic & Medicinal Chemistry
|February 13, 2007
Summary
New dibenzothiazole compounds show promise as amyloid-imaging agents for Alzheimer's disease. These agents exhibit high binding affinity and good brain uptake, aiding in the diagnosis of neurodegenerative disorders.
Area of Science:
- Medicinal Chemistry
- Neuroimaging
- Pharmacology
Background:
- Alzheimer's disease (AD) diagnosis relies on identifying amyloid plaques.
- Development of specific and sensitive imaging agents is crucial for early detection.
Purpose of the Study:
- To synthesize and evaluate novel dibenzothiazole derivatives as potential amyloid-imaging agents for AD.
- To investigate the structure-activity relationships of these compounds.
Main Methods:
- Synthesis of dibenzothiazole derivatives.
- In vitro binding studies using AD brain homogenates.
- Radiolabeling of a lead compound with iodine-125.
- In vivo brain uptake and washout studies in mice.
Main Results:
- Dibenzothiazole derivatives showed high binding affinities (nanomolar range) for amyloid.
- Electron-donating groups enhanced binding affinity.
- A lead compound demonstrated good brain uptake and rapid washout from normal brain tissue.
Conclusions:
- Lipophilic dibenzothiazole derivatives are a promising pharmacophore for developing novel amyloid-imaging agents.
- These agents hold potential for diagnosing Alzheimer's disease and related neurodegenerative disorders.
